286 related articles for article (PubMed ID: 37248320)
1. Grade scoring system reveals distinct molecular subtypes and identifies KIF20A as a novel biomarker for predicting temozolomide treatment efficiency in gliomas.
Ye L; Tong S; Wang Y; Wang Y; Ma W
J Cancer Res Clin Oncol; 2023 Sep; 149(12):9857-9876. PubMed ID: 37248320
[TBL] [Abstract][Full Text] [Related]
2. [Single-cell transcriptome analysis of multigrade glioma heterogeneity and immune microenvironment revealed potential prognostic biomarkers].
Liu J; Xu K; Ma L; Wang Y
Sheng Wu Gong Cheng Xue Bao; 2022 Oct; 38(10):3790-3808. PubMed ID: 36305410
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive analysis of m
Zhao K; Li W; Yang Y; Hu X; Dai Y; Huang M; Luo J; Zhang K; Zhao N
Front Immunol; 2022; 13():955848. PubMed ID: 36203569
[TBL] [Abstract][Full Text] [Related]
4. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
Front Immunol; 2022; 13():899710. PubMed ID: 35677036
[TBL] [Abstract][Full Text] [Related]
5. Role of COL6A2 in malignant progression and temozolomide resistance of glioma.
Hong X; Zhang J; Zou J; Ouyang J; Xiao B; Wang P; Peng X
Cell Signal; 2023 Feb; 102():110560. PubMed ID: 36521657
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive Analysis Reveals a 4-Gene Signature in Predicting Response to Temozolomide in Low-Grade Glioma Patients.
Wang Q; He Z; Chen Y
Cancer Control; 2019; 26(1):1073274819855118. PubMed ID: 31167546
[TBL] [Abstract][Full Text] [Related]
7. Elucidating the Role of Pyroptosis in Lower-Grade Glioma: Development of a Novel Scoring System to Enhance Personalized Therapeutic Approaches.
Chen X; Xu Y; Wang M; Ren C
J Mol Neurosci; 2023 Aug; 73(7-8):649-663. PubMed ID: 37566191
[TBL] [Abstract][Full Text] [Related]
8. Grade II/III Glioma Microenvironment Mining and Its Prognostic Merit.
Chen J; Hou C; Wang P; Yang Y; Zhou D
World Neurosurg; 2019 Dec; 132():e76-e88. PubMed ID: 31518750
[TBL] [Abstract][Full Text] [Related]
9. Intrinsic immune evasion patterns predict temozolomide sensitivity and immunotherapy response in lower-grade gliomas.
Tu Z; Ji Q; Han Q; Long X; Li J; Wu L; Huang K; Zhu X
BMC Cancer; 2022 Sep; 22(1):973. PubMed ID: 36096781
[TBL] [Abstract][Full Text] [Related]
10. BCL7A as a novel prognostic biomarker for glioma patients.
Liu J; Gao L; Ji B; Geng R; Chen J; Tao X; Cai Q; Chen Z
J Transl Med; 2021 Aug; 19(1):335. PubMed ID: 34362400
[TBL] [Abstract][Full Text] [Related]
11. Signature Construction and Disulfidptosis-Related Molecular Cluster Identification for Better Prediction of Prognosis in Glioma.
Zhuang Y; Chen J; Mai Z; Huang W; Zhong W
J Mol Neurosci; 2024 Apr; 74(2):38. PubMed ID: 38573391
[TBL] [Abstract][Full Text] [Related]
12. Investigation of Genetic Determinants of Glioma Immune Phenotype by Integrative Immunogenomic Scale Analysis.
Zhao B; Wang Y; Wang Y; Dai C; Wang Y; Ma W
Front Immunol; 2021; 12():557994. PubMed ID: 34220791
[TBL] [Abstract][Full Text] [Related]
13. Integrated profiling identifies CACNG3 as a prognostic biomarker for patients with glioma.
Shan E; Cao YN; Zhang Y; Chen W; Ren X; Zhu S; Xi X; Mu S; Ma M; Zhi T; Li X
BMC Cancer; 2023 Sep; 23(1):846. PubMed ID: 37697240
[TBL] [Abstract][Full Text] [Related]
14. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
[TBL] [Abstract][Full Text] [Related]
15. Characterization of DNA Damage Repair Related Signature and Molecular Feature in Low-Grade Gliomas to Aid Chemotherapy and Drug Discovery.
Yin X; Li M; He Z
Front Biosci (Landmark Ed); 2023 Oct; 28(10):234. PubMed ID: 37919061
[TBL] [Abstract][Full Text] [Related]
16. Prediction and analysis of hub genes between glioblastoma and low-grade glioma using bioinformatics analysis.
Xu B
Medicine (Baltimore); 2021 Jan; 100(3):e23513. PubMed ID: 33545929
[TBL] [Abstract][Full Text] [Related]
17. Weighted gene correlation network analysis identifies microenvironment-related genes signature as prognostic candidate for Grade II/III glioma.
Li Y; Deng G; Zhang H; Qi Y; Gao L; Tan Y; Hu P; Wang Y; Liu B; Chen Q
Aging (Albany NY); 2020 Nov; 12(21):22122-22138. PubMed ID: 33186124
[TBL] [Abstract][Full Text] [Related]
18. Liquid-liquid phase separation-related gene in gliomas: FABP5 is a potential prognostic marker.
Tang Q; Mao X; Chen Z; Ma C; Tu Y; Zhu Q; Lu J; Wang Z; Zhang Q; Wu W
J Gene Med; 2023 Oct; 25(10):e3517. PubMed ID: 37114595
[TBL] [Abstract][Full Text] [Related]
19. MCM10 as a novel prognostic biomarker and its relevance to immune infiltration in gliomas.
Tian QS; Zhang Q; Huang W
Technol Health Care; 2023; 31(4):1301-1317. PubMed ID: 36872806
[TBL] [Abstract][Full Text] [Related]
20. Selenoprotein GPX1 is a prognostic and chemotherapy-related biomarker for brain lower grade glioma.
Chen X; Fu G; Li L; Zhao Q; Ke Z; Zhang R
J Trace Elem Med Biol; 2022 Dec; 74():127082. PubMed ID: 36155420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
